EU Recommends Using U-Systems' somo*v With Mammography For Breast Cancer Screening

Early detection of cancer is the main goal of any screening program around the world. Regarding breast cancer, both symptomatic and asymptomatic patients, even those with dense breasts, currently in Europe have a high potential for early diagnosis, thus offering a great opportunity to start treatment as early as possible. The European Union gave a CE clearance for U-Systems’ somo•v automated breast ultrasound (ABUS) system to be used in conjugation with traditional mammography for breast cancer screening. It is not slated for ABUS system to replace traditional mammography screening, rather, it will be used in conjugation with it increasing early detection of patients, as CEO Ron Ho, in a U-Systems press release illustrated, “We have strong scientific evidence that for women with dense breast tissue, supplementing mammograms with somo•v ABUS can substantially increase breast cancer detection.”

GE Healthcare To Lead U.S. Ultrasound Market In The Next Years

Millennium Research Group (MRG) predicts a robust growth for GE Healthcare during 2014. GE Healthcare was a major leader of the U.S. ultrasound system market in 2009 as well as its strength in the fast-growing emerging ultrasound system, therefore MRG expects further success and progress for the company. The continued growth of GE Healthcare enables it to increase its lead over Philips and Siemens in a market that is projected to be at $1.2 billion in the United States.

Low Infection Rates With Ultrasound-guided Procedures

According to a new study, the occurrence of infection after ultrasound-guided procedures is very low. The study included reviewing several types of these procedures such as fine-needle aspiration and thoracentesis, which involves needle draining of fluids from the thoracic cavity. The study is going to appear in the October issue of the American Journal of Roentgenology. Ultrasound is one of the major medical imaging techniques that uses sound waves to generate images of the internal organs. The technique is preferred due to its high safety profile, especially for pregnant women and children.

Ultrasound Provides New options For Self-embedding Patients

In a new study, ultrasound scanning was used as a minimally-invasive technique for detection and treatment of a behavioral disorder called self-embedding, where patients tend to cause injuries to themselves. The findings of the study will be highlighted in the online edition and October print issue of the journal Radiology.

Siemens Will Display Next-Generation Ultrasound At BMUS 2010

Siemens Healthcare will display its ultrasound range, including the Acuson S2000 2.0 and Acuson X300 Premium Edition at 2010 British Medical Ultrasound Society (BMUS) Annual Scientific Meeting and Exhibition which will be held in Brighton from 28-30 September.

Hitachi And RSNA Grant Their Awards To Ultrasound Researchers

Hitachi Medical Systems, a major company providing medical imaging systems, and the Radiological Society of North America (RSNA) Research & Education (R & E) Foundation,  have recently awarded their Hitachi Medical Systems/RSNA Research Seed Grant to a couple of researchers, Omolola Atalabi, M.B.B.S. and Sidhartha Tavri, M.B.B.S. Atalabi, a researcher at the University College Hospital, University of Ibadan, Nigeria was awarded $30,000 by Hitachi/RSNA to aid her in his researches for new medical and technical options while using ultrasound with children.

Lantheus To Provide DEFINITY In India

Lantheus Medical Imaging, Inc., a leading company offering diagnostic imaging solutions, announced that it has provided its DEFINITY® Vial, an ultrasound contrast imaging agent, in the market in India. Lantheus has closed a deal with J.B. Chemicals & Pharmaceuticals, Ltd. (JBCPL), a major company located in Mumbai,to distribute and market DEFINITY in India. DEFINITY, a Perflutren Lipid Microsphere ultrasound contrast agent, is already available in markets of Australia, New Zealand in addition to North America and several countries in the Middle East. In India, DEFINITY®  is indicated for patients with suboptimal echocardiograms, as it opacifys the left ventricle in addition to enhancing the delineation of the left ventricular endocardial border, it can also be sued in patients for contrast-enhanced diagnostic ultrasound imaging for better reviewing of focal lesions of the kidney and liver.

http://www.healthimaginghub.com/article/1592-lantheus-to-provide-definity-in-india.html